Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature
Open accessThe DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index; 18 of the 38 sources its claims cite were checked for support.
Abstract
Rationale Methamphetamine use and related harms have risen at alarming rates. While several psychosocial and pharmacologic interventions have been described in the literature, there is uncertainty regarding the best approach for the management of methamphetamine use disorder (MUD) and problematic methamphetamine use (PMU). We conducted a scoping review of recent systematic reviews (SR), clinical practice guidelines (CPG), and primary controlled studies of psychosocial and pharmacologic treatments for MUD/PMU. Methods Guided by an a priori protocol, electronic database search updates (e.g., MEDLINE, Embase) were performed in February 2022. Screening was performed following a two-stage process, leveraging artificial intelligence to increase efficiency of title and abstract screening. Studies involving individuals who use methamphetamine, including key subgroups (e.g. those with mental health comorbidities; adolescents/youths; gay, bisexual, and other men who have sex with men) were sought. We examined evidence related to methamphetamine use, relapse, use of other substances, risk behaviors, mental health, harms, and retention. Figures, tables and descriptive synthesis were used to present findings from the identified literature. Results We identified 2 SRs, one CPG, and 54 primary studies reported in 69 publications that met our eligibility criteria. Amongst SRs, one concluded that psychostimulants had no effect on methamphetamine abstinence or treatment retention while the other reported no effect of topiramate on cravings. The CPG strongly recommended psychosocial interventions as well as self-help and family support groups for post-acute management of methamphetamine-related disorders. Amongst primary studies, many interventions were assessed by only single studies; contingency management was the therapy most commonly associated with evidence of potential effectiveness, while bupropion and modafinil were analogously the most common pharmacologic interventions. Nearly all interventions showed signs of potential benefit on at least one methamphetamine-related outcome measure. Discussion This scoping review provides an overview of available interventions for the treatment of MUD/PMU. As most interventions were reported by a single study, the effectiveness of available interventions remains uncertain. Primary studies with longer durations of treatment and follow-up, larger sample sizes, and of special populations are required for conclusive recommendations of best approaches for the treatment of MUD/PMU. Copyright: © 2023 Hersi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Overview
CoChat Summary
## TL;DR
This scoping review mapped recent systematic reviews, one clinical practice guideline, and primary controlled studies of psychosocial and pharmacologic interventions for methamphetamine use disorder/problematic methamphetamine use. The evidence base was sparse and heterogeneous, so the authors conclude that the effectiveness of most interventions remains uncertain.
## Key findings
- The review identified 2 systematic reviews, 1 clinical practice guideline, and 54 primary studies in 69 publications that met eligibility criteria.
- In the primary-study evidence, 952 treatment-effect estimates were charted; the most commonly reported outcomes were retention/dropout (45 studies, 249 estimates), methamphetamine use and abstinence (32 studies, 253 estimates), and change in methamphetamine use (34 studies, 139 estimates).
- Contingency management was the psychosocial therapy most commonly associated with evidence of potential effectiveness, while bupropion and modafinil were the most common pharmacologic interventions; the paper also notes that nearly all interventions showed signs of potential benefit on at least one methamphetamine-related outcome measure.
- The included guideline strongly recommended psychosocial interventions, including self-help and family support groups, and also recommended disease-specific evidence-based treatment and psychoeducation for co-occurring mental health and substance use conditions.
## Methods
- Design: Scoping review, guided by an a priori protocol and reported using PRISMA-ScR; the protocol was published and registered on the Open Science Framework.
- Data/sample: Recent SRs and CPGs published 2015 or later, plus primary controlled studies in people who use methamphetamine, including key subgroups (e.g., mental health comorbidities, adolescents/youth, gbMSM, pregnant people, correctional populations); searches were updated in February 2022.
- Main analysis: Study selection and extraction were done with two-stage screening; SRs/CPGs were quality appraised with AMSTAR-2 and AGREE-2; primary-study findings were synthesized with vote counting based on direction of effect and descriptive/narrative summaries, and the feasibility of network meta-analysis was assessed.
## Limitations
- The paper states that, consistent with scoping review methods, it used a high-level synthesis that often required consolidating similar outcomes despite differences in how they were defined or measured.
- The vote-counting approach did not account for effect size, statistical significance, or sample-size differences across studies, which the authors say limits the conclusions that can be drawn.
- The evidence base was sparse and heterogeneous, with many interventions evaluated in only a single study; additionally, the review was limited to English and French publications, so the paper notes it is unknown whether excluded-language studies would have met eligibility criteria.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
10 Valid · 1 Not valid · 11 Not checked · 62 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Although various pharmacologic (e.g., bupropion [22, 23], mirtazapine [24, 25], varenicline [26]) and psychosocial (e.g., cognitive behavioural therapy [27], contingency management [28, 29], Matrix model [30]) therapies for MUD/PMU have been explored in the literature, the best approach to treatment remains unclear.”
§ Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature > Background
What the sources say
- Not checked — no full text of the sourcecites [22] AM Elkashef, 2008, Bupropion for the treatment of methamphetamine dependence, Neuropsychopharmacology source
- Supportedcites [23] KG Heinzerling, 2014, Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use, Addiction source
The citation identifies bupropion as an explored pharmacologic treatment. The Discussion reports this paper's bupropion trial in participants with methamphetamine dependence, so the source is an example of the treatment literature cited; it need not cover the other therapies listed with separate citations. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [27] A Baker, 2005, Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction, Addiction source
- Not checked — no full text of the sourcecites [28] JM Roll, 2006, Contingency management: schedule effects, Psychiatry Res source
- Supportedcites [29] JM Roll, 2013, Duration effects in contingency management treatment of methamphetamine disorders, Addict Behav source
The citation to Roll (2013) is attached to contingency management, not to the sentence’s list of pharmacologic therapies. The Methods (Study Procedures) describe a trial of three durations of contingency management alongside psychosocial treatment for methamphetamine dependence, and the Discussion reports its results. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Review authors from both SRs concluded that there was no evidence of an effect of psychostimulants on terminal abstinence (i.e., maintaining abstinence from methamphetamine at the end of the trial) and treatment retention in the context of amphetamine and methamphetamine use disorder [108]”
§ Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature > Results > Objective 1: What are the key characteristics and recommendations/findings of recent CPGs and SRs that address psychosocial and pharmacologic treatment of MUD/PMU?
What the sources say
- Supportedcites [108] M Bhatt, 2016, Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis, Syst Rev source
The Results section defines terminal abstinence as methamphetamine-free urine screens during the final two weeks of a trial and reports no significant effect of psychostimulants on that outcome. The Abstract Results and Conclusions also report no overall effect on treatment retention among patients with amphetamine and methamphetamine use disorders. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Among studies reporting race (n = 34), the majority of patients were Caucasian in all but four studies [23, 69, 73, 102].”
§ Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature > Results > Objective 2: What are the key characteristics (e.g., types of patients enrolled, treatments compared, outcomes assessed) of available primary controlled studies evaluating the clinical benefits of psychosocial and pharmacologic treatment of MUD/PMU?
What the sources say
- Could not verifycites [23] KG Heinzerling, 2014, Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use, Addiction sourceExperimental — accuracy not yet measured
The Results section (Sample Characteristics; page unavailable) says participant demographics are shown in Table 1, but the passages available from our copy do not give the racial breakdown. Searches for Caucasian, White, race, and ethnicity did not establish whether this trial was one of the four exceptions. This single trial also cannot establish the citing paper’s count across 34 studies. (LLM, conf=0.72)
- Not checked — no full text of the sourcecites [69] U Perngparn, 2011, Methamphetamine dependence treatment rehabilitation in Thailand: a model assessment, J Med Assoc Thai
- Supportedcites [73] CJ Reback, 2019, Theory-Based Text-Messaging to Reduce Methamphetamine Use and HIV Sexual Risk Behaviors Among Men Who Have Sex with Men: Automated Unidirectional Delivery Outperforms Bidirectional Peer Interactive Delivery, AIDS Behav source
The citation identifies this paper as one of the four exceptions to the Caucasian-majority pattern, rather than as the source of the 34-study count. In Results > Participant Characteristics, its participants are predominantly African American/Black (44%) or Hispanic/Latino (25%); the Discussion likewise describes the sample as predominantly racial/ethnic minority MSM. (LLM, conf=0.90)
- Supportedcites [102] K Sorsdahl, 2021, A novel brief treatment for methamphetamine use disorders in South Africa: a randomised feasibility trial, Addict Sci Clin Pract source
The Results (Table 1) report that 53 of 60 participants were classified as Coloured, five as Black, and two as White. This supports citing the trial as one of the four studies without a Caucasian majority; the count of 34 studies is the citing paper’s own summary, not a finding attributed to this trial. (LLM, conf=0.93)
plainn = 34- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Using the AMSTAR-2 instrument (assessments provided in S6 Text), one review was rated to be of low quality [108] due to the presence of one critical flaw (i.e., did not provide a list of studies evaluated at full-text that were excluded) and two non-critical weaknesses (i.e., did not describe for inclusion of study designs, did not perform data extraction in duplicate);”
§ Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature > Results > Objective 1: What are the key characteristics and recommendations/findings of recent CPGs and SRs that address psychosocial and pharmacologic treatment of MUD/PMU?
What the sources say
- Supportedcites [108] M Bhatt, 2016, Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis, Syst Rev source
The Methods and Strengths and limitations sections identify the cited work as a systematic review of psychostimulants for amphetamine and methamphetamine use disorders. The citation identifies the review being assessed; the AMSTAR-2 rating is presented as the citing authors’ own assessment, not a rating reported by the review. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim have been checked yet.
In the paper
“Amongst SRs, one concluded that psychostimulants had no effect on methamphetamine abstinence or treatment retention while the other reported no effect of topiramate on cravings.”
§ Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
24 more claims
Create a free account to see all 84 claims and to verify the 3 references still open.
- Probably not a substantial claim. 34
- It may state two separate claims as one. 36
- Borderline: one of the tests for a substantial claim is unclear. 1
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
Tricco, A. C., Lillie, E., Zarin, W., O'Brien, K. K., Colquhoun, H., Levac, D., Moher, D., Peters, M. D. J., Horsley, T., Weeks, L., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0850 · Cited by 43,565 · cited 2×
“We report the review in accordance with the PRISMA Extension Statement for Scoping Reviews [33] (S1 Text).”
MethodScoping studies: towards a methodological framework
Arksey, H., & O'Malley, L. (2005) · International Journal of Social Research Methodology · doi:10.1080/1364557032000119616 · Cited by 36,742 · cited 1×
“This systematic scoping review was guided by established scoping review methodology [32].”
MethodShea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., et al. (2017) · BMJ · doi:10.1136/bmj.j4008 · Cited by 10,636
Self-citationClinical Practice Guidelines We Can Trust
Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Board on Health Care Services, & Institute of Medicine (2011) · National Academies Press eBooks · doi:10.17226/13058 · Cited by 3,081 · cited 1×
“CPGs had to meet the following criteria: (i) diverse and relevant stakeholders included in guideline development panel; (ii) consensus procedure and methods for guideline development were reported; (iii) funding and the conflicts of interest (financial and non-financial) disclosed for members of the panel; (iv) system…”
MethodThe COMET Handbook: version 1.0
Williamson, P. R., Altman, D. G., Bagley, H., Barnes, K. L., Blazeby, J. M., Brookes, S. T., Clarke, M., Gargon, E., Gorst, S., Harman, N., et al. (2017) · Trials · doi:10.1186/s13063-017-1978-4 · Cited by 2,011
Simultaneous comparison of multiple treatments: Combining direct and indirect evidence.
Caldwell, D. M., Ades, A. E., & Higgins, J. P. T. (2005) · BMJ · doi:10.1136/bmj.331.7521.897 · Cited by 1,600 · cited 5×
“Assessments of the comparative benefits and harms of different treatments for MUD/PMU using evidence synthesis techniques such as network meta-analysis (NMA) may also provide new insights.”
InfluentialEvidence summaries: the evolution of a rapid review approach
Khangura, S., Konnyu, K., Cushman, R., Grimshaw, J., & Moher, D. (2012) · Systematic Reviews · doi:10.1186/2046-4053-1-10 · Cited by 1,232 · cited 1×
“, one reviewer was required to include a record, and two reviewers to exclude) [39].”
BackgroundGuidelines International Network: Toward International Standards for Clinical Practice Guidelines
Qaseem, A., Forland, F., Macbeth, F., Ollenschläger, G., Phillips, S., van der Wees, P., & for the Board of Trustees of the Guidelines International Network* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-7-201204030-00009 · Cited by 902 · cited 1×
“CPGs had to meet the following criteria: (i) diverse and relevant stakeholders included in guideline development panel; (ii) consensus procedure and methods for guideline development were reported; (iii) funding and the conflicts of interest (financial and non-financial) disclosed for members of the panel; (iv) system…”
MethodAGREE II: advancing guideline development, reporting, and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Preventive Medicine · doi:10.1016/j.ypmed.2010.08.005 · Cited by 758 · cited 14×
“With regard to CPGs, we required articles presenting recommendations to meet a very thorough set of methods in their design, and we acknowledge the availability of other CPGs related to PMU/MUD which may also be of clinical interest to readers [110].”
MethodInfluentialSynthesizing and presenting findings using other methods
McKenzie, J. E., & Brennan, S. E. (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch12 · Cited by 423
A multi‐site comparison of psychosocial approaches for the treatment of methamphetamine dependence
Rawson, R. A., Marinelli‐Casey, P., Anglin, M. D., Dickow, A., Frazier, Y., Gallagher, C., Galloway, G. P., Herrell, J., Huber, A., McCann, M. J., et al. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00707.x · Cited by 387
(1998) · Europe PMC (PubMed Central) · Cited by 336
Shoptaw, S., Reback, C. J., Peck, J. A., Yang, X., Rotheram-Fuller, E., Larkins, S., Veniegas, R. C., Freese, T. E., & Hucks-Ortiz, C. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.10.004 · Cited by 313 · cited 7×
“In consideration of all • CM (voucher based), gay and bisexual men-specific CBT alone or with CM were all favored to CBT alone [77, 85, 93], and interventions involving CM (voucher based) were favored to gb men-specific CBT [77, 85, 93] • Gay specific CBT was favored to Gay social support therapy for both meth use/ ab…”
BackgroundMethodInfluentialPsychosocial interventions for cannabis use disorder
Gates, P. J., Sabioni, P., Copeland, J., Le Foll, B., & Gowing, L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005336.pub4 · Cited by 282 · cited 1×
“, in-treatment or treatment seeking) [20, 21].”
Bupropion and naltrexone in methamphetamine use disorder
Trivedi, M. H., Walker, R., Ling, W., dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2020214 · Cited by 281
Bupropion for the treatment of methamphetamine dependence
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301481 · Cited by 234
Baker, A., Lee, N. K., Claire, M., Lewin, T. J., Grant, T., Pohlman, S., Saunders, J. B., Kay‐Lambkin, F., Constable, P., Jenner, L., et al. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01002.x · Cited by 227
Drugs and sexual effects: role of drug type and gender
Rawson, R. A., Washton, A., Domier, C. P., & Reiber, C. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(01)00215-x · Cited by 209
Contingency Management for the Treatment of Methamphetamine Use Disorders
Roll, J. M., Petry, N. M., Stitzer, M. L., Brecht, M. L., Peirce, J. M., McCann, M. J., Blaine, J., MacDonald, M., DiMaria, J., Lucero, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1993 · Cited by 197 · cited 1×
“Escalating with reset CM; Escalating without reset CM [28] CM + treatment as usual; Treatment as usual [72] • CM performed better than no treatment or standard treatment alone [29, 52, 72] • More CM sessions or longer periods of session outperformed fewer sessions and shorter periods [29] • Escalating with reset CM ou…”
BackgroundContingency Management for the Treatment of Methamphetamine Use Disorders
Roll, J. M., Petry, N. M., Stitzer, M. L., Brecht, M. L., Peirce, J. M., McCann, M. J., Blaine, J., MacDonald, M., DiMaria, J., Lucero, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.11.1993 · Cited by 196
McKetin, R., Lubman, D. I., Najman, J. M., Dawe, S., Butterworth, P., & Baker, A. L. (2014) · Addiction · doi:10.1111/add.12474 · Cited by 181
Mirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial
Colfax, G. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.124 · Cited by 175 · cited 4×
“, bupropion [22, 23], mirtazapine [24, 25], varenicline [26]) and psychosocial (e.”
BackgroundInfluentialRandomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence
SHOPTAW, S. J., Heinzerling, K. G., Rotheram-Fuller, E. J., Steward, T., Wang, J., Swanson, A., Garza, R. D. L., Newton, T., & Ling, W. W. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.03.010 · Cited by 169 · cited 4×
“• Aripiprazole [54], Bupropion [22, 23, 50, 80, 84, 90], Methylphenidate [66, 103], Modafinil (200 mg and 400 mg) [49, 62, 76, 96], PROMETA protocol [65], and Nacetyl cysteine [101] provided mixed results (i.”
BackgroundInfluentialMethamphetamine abuse and dentistry
Hamamoto, D., & Rhodus, N. (2009) · Oral Diseases · doi:10.1111/j.1601-0825.2008.01459.x · Cited by 166
A double‐blind, placebo‐controlled trial of modafinil (200 mg/day) for methamphetamine dependence
Shearer, J., Darke, S., Rodgers, C., Slade, T., Van Beek, I., Lewis, J., Brady, D., McKetin, R., Mattick, R. P., & Wodak, A. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02437.x · Cited by 159
SHOPTAW, S. J., Huber, A., Peck, J. A., Yang, X., Liu, J., Dang, J., Roll, J. M., Shapiro, B., Rotheram-Fuller, E. J., & Ling, W. W. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.03.005 · Cited by 156 · cited 2×
“Matrix model; Methylphenidate; Matrix model + Methylphenidate; No treatment [104] • Among studies that evaluated pharmacological and behavioural interventions combined, theextent of benefits varied by outcome measure [78, 97, 104] • When comparing a behavioral intervention to a pharmacotherapy intervention, CBT tended…”
BackgroundMcKetin, R., Najman, J. M., Baker, A. L., Lubman, D. I., Dawe, S., Ali, R., Lee, N. K., Mattick, R. P., & Mamun, A. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03933.x · Cited by 147 · cited 3×
“, outpatient counseling, community-based residential rehabilitation and community-based detox [53, 91, 92], blended imaging desensitisation [102], educational intervention [60]) outperformed treatment as usual/no treatment for most outcomes (e.”
MethodResultCoffin, P. O., Santos, G.-M., Hern, J., Vittinghoff, E., Walker, J. E., Matheson, T., Santos, D., Colfax, G., & Batki, S. L. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.3655 · Cited by 139 · cited 4×
“, bupropion [22, 23], mirtazapine [24, 25], varenicline [26]) and psychosocial (e.”
BackgroundInfluentialSmout, M. F., Longo, M., Harrison, S., Minniti, R., Wickes, W., & White, J. M. (2010) · Substance Abuse · doi:10.1080/08897071003641578 · Cited by 129 · cited 6×
“In consideration of all • CM (voucher based), gay and bisexual men-specific CBT alone or with CM were all favored to CBT alone [77, 85, 93], and interventions involving CM (voucher based) were favored to gb men-specific CBT [77, 85, 93] • Gay specific CBT was favored to Gay social support therapy for both meth use/ ab…”
ResultInfluentialLongo, M., Wickes, W., Smout, M., Harrison, S., Cahill, S., & White, J. M. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02717.x · Cited by 122
Modafinil for the treatment of methamphetamine dependence
Anderson, A. L., Li, S.-H., Biswas, K., McSherry, F., Holmes, T., Iturriaga, E., Kahn, R., Chiang, N., Beresford, T., Campbell, J., et al. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.07.007 · Cited by 117 · cited 6×
“, related to degree of benefit) when compared to placebo depending on the outcome • Unclear reporting of results in the Topiramate study did not allow for determination of which was favored [57, 89] • Approximately half of the pharmacological therapy studies reported on harms often favoring placebo or no difference be…”
BackgroundResultInfluentialTopiramate for the treatment of methamphetamine addiction: a multi‐center placebo‐controlled trial
Elkashef, A., Kahn, R., Yu, E., Iturriaga, E., Li, S., Anderson, A., Chiang, N., Ait‐Daoud, N., Weiss, D., McSherry, F., et al. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03771.x · Cited by 116 · cited 1×
“, related to degree of benefit) when compared to placebo depending on the outcome • Unclear reporting of results in the Topiramate study did not allow for determination of which was favored [57, 89] • Approximately half of the pharmacological therapy studies reported on harms often favoring placebo or no difference be…”
ResultImpact of methamphetamine on infection and immunity
Salamanca, S. A., Sorrentino, E. E., Nosanchuk, J. D., & Martinez, L. R. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00445 · Cited by 116
Cope, S., Zhang, J., Saletan, S., Smiechowski, B., Jansen, J. P., & Schmid, P. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-93 · Cited by 110 · cited 1×
“[45] and inspected the studies with regard to network connectivity, the similarity of interventions (e.”
BackgroundHeinzerling, K. G., SHOPTAW, S. J., Peck, J. A., Yang, X., Liu, J., Roll, J. M., & Ling, W. W. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.03.019 · Cited by 110 · cited 4×
“Acceptance and Commitment Therapy vs CBT [81] More CBT sessions over fewer sessions, and CBT over self-help booklet with the exception of self-help booklet outperforming 1-session of CBT [27, 87, 88] • Variation in outcome results between ACT and CBT with no difference in harms [81] Other behavioural interventions (n…”
BackgroundResultInfluentialDarke, S., Torok, M., Kaye, S., Ross, J., & McKetin, R. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02872.x · Cited by 106
Heinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105 · cited 5×
“Naltrexone; Placebo [55] 3.”
BackgroundInfluentialOutcomes using two tailored behavioral treatments for substance abuse in urban gay and bisexual men
SHOPTAW, S. J., Reback, C. J., Larkins, S., Wang, P., Rotheram-Fuller, E. J., Dang, J., & Yang, X. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.11.004 · Cited by 90 · cited 2×
“Behavioural activation + Sexual risk reduction counselling; Sexual risk reduction counselling [68] • CM (voucher based), gay and bisexual men-specific CBT alone or with CM were all favored to CBT alone [77, 85, 93], and interventions involving CM (voucher based) were favored to gb men-specific CBT [77, 85, 93] • Gay s…”
BackgroundMethodPeck, J. A., Reback, C. J., Yang, X., Rotheram-Fuller, E., & Shoptaw, S. (2005) · Journal of Urban Health · doi:10.1093/jurban/jti029 · Cited by 82 · cited 7×
“In consideration of all • CM (voucher based), gay and bisexual men-specific CBT alone or with CM were all favored to CBT alone [77, 85, 93], and interventions involving CM (voucher based) were favored to gb men-specific CBT [77, 85, 93] • Gay specific CBT was favored to Gay social support therapy for both meth use/ ab…”
BackgroundMethodInfluentialLing, W., Chang, L., Hillhouse, M., Ang, A., Striebel, J., Jenkins, J., Hernandez, J., Olaer, M., Mooney, L., Reed, S., et al. (2014) · Addiction · doi:10.1111/add.12608 · Cited by 81
Harms, R., Morsey, B., Boyer, C. W., Fox, H. S., & Sarvetnick, N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049897 · Cited by 81
A controlled trial of imipramine for the treatment of methamphetamine dependence
Galloway, G. P., Newmeyer, J. A., Knapp, T., Stalcup, S. A., & Smith, D. E. (1996) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(96)00154-7 · Cited by 77 · cited 3×
“• Aripiprazole [54], Bupropion [22, 23, 50, 80, 84, 90], Methylphenidate [66, 103], Modafinil (200 mg and 400 mg) [49, 62, 76, 96], PROMETA protocol [65], and N-acetyl cysteine [101] provided mixed results (i.e., related to degree of benefit) when compared to placebo depending on the outcome • Unclear reporting of res…”
BackgroundResultReback, C. J., Fletcher, J. B., Swendeman, D. A., & Metzner, M. (2019) · AIDS and Behavior · doi:10.1007/s10461-018-2225-z · Cited by 72 · cited 3×
“Combined (Interactive text message with peer health educator + Automated gay-specific text message + Weekly self-monitoring text-based assessment); Automated+ (Automated gay-specific text message + Weekly self-monitoring textbased assessment); Weekly self-monitoring text-based assessment [73] 5.”
BackgroundResultAnderson, A. L., Li, S.-H., Markova, D., Holmes, T. H., Chiang, N., Kahn, R., Campbell, J., Dickerson, D. L., Galloway, G. P., Haning, W., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.036 · Cited by 70 · cited 5×
“Citicoline; Placebo [51] • Paliperidone [83] and Citicoline [51] was mostly favored to placebo, and Bupropion [22, 50, 90] had unclear reporting of results.”
BackgroundInfluentialMethamphetamine Use and Violent Behavior: User Perceptions and Predictors
Brecht, M.-L., & Herbeck, D. M. (2013) · Journal of Drug Issues · doi:10.1177/0022042613491098 · Cited by 70
Oral manifestations of illicit drug use
Teoh, L., Moses, G., & McCullough, M. (2019) · Australian Dental Journal · doi:10.1111/adj.12709 · Cited by 69
Integration of existing systematic reviews into new reviews: identification of guidance needs
Robinson, K. A., Whitlock, E. P., Oneil, M. E., Anderson, J. K., Hartling, L., Dryden, D. M., Butler, M., Newberry, S. J., McPheeters, M., Berkman, N. D., et al. (2014) · Systematic Reviews · doi:10.1186/2046-4053-3-60 · Cited by 68 · cited 1×
“SRs had to meet the following criteria: (i)�2 databases searched; (ii) selection criteria reported; (iii) quality appraisal of included studies reported; and (iv) a list and synthesis of included studies reported [34, 35].”
BackgroundCoffin, P. O., Santos, G., Das, M., Santos, D. M., Huffaker, S., Matheson, T., Gasper, J., Vittinghoff, E., & Colfax, G. N. (2013) · Addiction · doi:10.1111/add.12073 · Cited by 67 · cited 1×
“• Aripiprazole [54], Bupropion [22, 23, 50, 80, 84, 90], Methylphenidate [66, 103], Modafinil (200 mg and 400 mg) [49, 62, 76, 96], PROMETA protocol [65], and Nacetyl cysteine [101] provided mixed results (i.”
BackgroundMethamphetamine dependence and human immunodeficiency virus risk behavior
Rawson, R. A., Gonzales, R. E., Antonini, V. P., Ang, A., Marinelli‐Casey, P., & Brummer, J. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.11.003 · Cited by 67 · cited 2×
“Educational intervention; Treatment as usual [60] • Matrix model outperformed both treatment as usual [70, 94, 95] and inpatient residential rehabilitation [69] with the exception of retention/dropout, where inpatient residential rehabilitation was favored [69] • Other interventions (i.”
MethodMethamphetamine Use and Criminal Behavior
Gizzi, M. C., & Gerkin, P. M. (2009) · International Journal of Offender Therapy and Comparative Criminology · doi:10.1177/0306624x09351825 · Cited by 67
Jaffe, A., Shoptaw, S., Stein, J. A., Reback, C. J., & Rotheram-Fuller, E. (2007) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.15.3.301 · Cited by 65 · cited 7×
“In consideration of all • CM (voucher based), gay and bisexual men-specific CBT alone or with CM were all favored to CBT alone [77, 85, 93], and interventions involving CM (voucher based) were favored to gb men-specific CBT [77, 85, 93] • Gay specific CBT was favored to Gay social support therapy for both meth use/ ab…”
BackgroundMethodInfluentialDuration effects in contingency management treatment of methamphetamine disorders
Roll, J. M., Chudzynski, J., Cameron, J. M., Howell, D. N., & McPherson, S. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2013.03.018 · Cited by 65 · cited 4×
“, cognitive behavioural therapy [27], contingency management [28, 29], Matrix model [30]) therapies for MUD/PMU have been explored in the literature, the best approach to treatment remains unclear.”
BackgroundInfluentialHeinzerling, K. G., Swanson, A., Hall, T. M., Yi, Y., Wu, Y., & Shoptaw, S. J. (2014) · Addiction · doi:10.1111/add.12636 · Cited by 64
Mimiaga, M. J., Pantalone, D. W., Biello, K. B., Hughto, J. M. W., Frank, J., O'Cleirigh, C., Reisner, S. L., Restar, A., Mayer, K. H., & Safren, S. A. (2019) · AIDS Care · doi:10.1080/09540121.2019.1595518 · Cited by 60 · cited 2×
“Behavioural activation + Sexual risk reduction counselling; Sexual risk reduction counselling [68] • CM (voucher based), gay and bisexual men-specific CBT alone or with CM were all favored to CBT alone [77, 85, 93], and interventions involving CM (voucher based) were favored to gb men-specific CBT [77, 85, 93] • Gay s…”
MethodResultBrown, E. S., & Gabrielson, B. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.05.006 · Cited by 58 · cited 5×
“Citicoline; Placebo [51] • Paliperidone [83] and Citicoline [51] was mostly favored to placebo, and Bupropion [22, 50, 90] had unclear reporting of results.”
BackgroundInfluentialRandomized Trial of Intensive Motivational Interviewing for Methamphetamine Dependence
Polcin, D. L., Bond, J., Korcha, R., Nayak, M. B., Galloway, G. P., & Evans, K. (2014) · Journal of Addictive Diseases · doi:10.1080/10550887.2014.950029 · Cited by 56 · cited 2×
“, cognitive behavioural therapy [27], contingency management [28, 29], Matrix model [30]) therapies for MUD/PMU have been explored in the literature, the best approach to treatment remains unclear.”
BackgroundBhatt, M., Zielinski, L., Baker-Beal, L., Bhatnagar, N., Mouravska, N., Laplante, P., Worster, A., Thabane, L., & Samaan, Z. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0370-x · Cited by 56
Roll, J. M., Huber, A., Sodano, R., Chudzynski, J. E., Moynier, E., & SHOPTAW, S. J. (2006) · The Psychological Record · doi:10.1007/bf03395538 · Cited by 55 · cited 1×
“5 CM schedules compared to each other [74] 4.”
BackgroundContingency management: schedule effects
Roll, J. M., & Shoptaw, S. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2005.12.003 · Cited by 54 · cited 2×
“, cognitive behavioural therapy [27], contingency management [28, 29], Matrix model [30]) therapies for MUD/PMU have been explored in the literature, the best approach to treatment remains unclear.”
BackgroundMcKetin, R., Kothe, A., Baker, A. L., Lee, N. K., Ross, J., & Lubman, D. I. (2018) · Drug and Alcohol Review · doi:10.1111/dar.12528 · Cited by 53 · cited 3×
“, outpatient counseling, community-based residential rehabilitation and community-based detox [53, 91, 92], blended imaging desensitisation [102], educational intervention [60]) outperformed treatment as usual/no treatment for most outcomes (e.”
MethodResultKrawczyk, C. S., Molitor, F., Ruiz, J., Facer, M., Allen, B., Green‐Ajufo, B., LYNCH, M., Klausner, J. D., McFarland, W., Bell-Sanford, G., et al. (2006) · PsycEXTRA Dataset · doi:10.1037/e494492006-002 · Cited by 48
Coffin, P. O., Santos, G., Hern, J., Vittinghoff, E., Santos, D., Matheson, T., Colfax, G., & Batki, S. L. (2018) · Addiction · doi:10.1111/add.13950 · Cited by 46
Zorick, T., Sugar, C. A., Hellemann, G., Shoptaw, S., & London, E. D. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.04.015 · Cited by 42 · cited 2×
“Matrix model; Methylphenidate; Matrix model + Methylphenidate; No treatment [104] • Among studies that evaluated pharmacological and behavioural interventions combined, theextent of benefits varied by outcome measure [78, 97, 104] • When comparing a behavioral intervention to a pharmacotherapy intervention, CBT tended…”
BackgroundMcCann, D. J., & Li, S. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00263.x · Cited by 41 · cited 5×
“Citicoline; Placebo [51] • Paliperidone [83] and Citicoline [51] was mostly favored to placebo, and Bupropion [22, 50, 90] had unclear reporting of results.”
BackgroundInfluentialCigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment
BRENSILVER, M., HEINZERLING, K. G., SWANSON, A., TELESCA, D., FURST, B. A., & SHOPTAW, S. J. (2013) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2012.00423.x · Cited by 39 · cited 4×
“• Aripiprazole [54], Bupropion [22, 23, 50, 80, 84, 90], Methylphenidate [66, 103], Modafinil (200 mg and 400 mg) [49, 62, 76, 96], PROMETA protocol [65], and Nacetyl cysteine [101] provided mixed results (i.”
BackgroundInfluentialHärtel-Petri, R., Krampe-Scheidler, A., Braunwarth, W.-D., Havemann-Reinecke, U., Jeschke, P., Looser, W., Mühlig, S., Schäfer, I., Scherbaum, N., Bothe, L., et al. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-105500 · Cited by 39
Kamp, F., Proebstl, L., Hager, L., Schreiber, A., Riebschläger, M., Neumann, S. J., Straif, M., Schacht-Jablonowsky, M., Manz, K. M., Soyka, M., et al. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.04.010 · Cited by 36
N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial
McKetin, R., Dean, O. M., Turner, A., Kelly, P. J., Quinn, B., Lubman, D. I., Dietze, P., Carter, G. L., Higgs, P., Sinclair, B., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101005 · Cited by 36
Double‐blind placebo‐controlled evaluation of the PROMETA™ protocol for methamphetamine dependence
Ling, W., Shoptaw, S., Hillhouse, M., Bholat, M. A., Charuvastra, C., Heinzerling, K., Chim, D., Annon, J., Dowling, P. T., & Doraimani, G. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03619.x · Cited by 35
Interventions for Substance Use Disorders in Adolescents: A Systematic Review
Steele, D. W., Becker, S. J., Danko, K. J., Balk, E. M., Saldanha, I. J., Adam, G. P., Bagley, S. M., Friedman, C., Spirito, A., Scott, K., et al. (2020) · doi:10.23970/ahrqepccer225 · Cited by 34
Ma, J. Z., Johnson, B. A., Yu, E., Weiss, D., McSherry, F., Saadvandi, J., Iturriaga, E., Ait‐Daoud, N., Rawson, R. A., Hrymoc, M., et al. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.10.009 · Cited by 33 · cited 1×
“, related to degree of benefit) when compared to placebo depending on the outcome • Unclear reporting of results in the Topiramate study did not allow for determination of which was favored [57, 89] • Approximately half of the pharmacological therapy studies reported on harms often favoring placebo or no difference be…”
ResultKorcha, R. A., Polcin, D. L., Evans, K., Bond, J. C., & Galloway, G. P. (2013) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2013.08.013 · Cited by 33 · cited 1×
“, intensive versus standard motivational interviewing [30, 86]) or unclear results due to poor reporting [46, 105] Behavioural + Pharmacotherapy interventions (n = 7 studies; 13 articles)”
BackgroundDas, M., Santos, D., Matheson, T., Santos, G.-M., Chu, P., Vittinghoff, E., Shoptaw, S., & Colfax, G. N. (2010) · AIDS · doi:10.1097/qad.0b013e328336e98b · Cited by 32
The Effect of Buprenorphine on Methamphetamine Cravings
Salehi, M., Emadossadat, A., Kheirabadi, G. R., Maracy, M. R., & Sharbafchi, M. R. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000408 · Cited by 32 · cited 2×
“Acceptance and Commitment Therapy vs CBT [81] More CBT sessions over fewer sessions, and CBT over self-help booklet with the exception of self-help booklet outperforming 1-session of CBT [27, 87, 88] • Variation in outcome results between ACT and CBT with no difference in harms [81] Other behavioural interventions (n…”
BackgroundLee, N., Pohlman, S., Baker, A., Ferris, J., & KAY‐LAMBKIN, F. J. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2009.12.006 · Cited by 31 · cited 9×
“When comparing number of session, 2-session CBT was favored when compared to the others [27, 87, 88].”
ResultInfluentialAryan, N., Banafshe, H. R., Farnia, V., Shakeri, J., Alikhani, M., Rahimi, H., Sehat, M., Mamsharifi, P., Ghaderi, A., & Omidi, A. (2020) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-020-00317-y · Cited by 31
Heinzerling, K. G., Briones, M., Thames, A. D., Hinkin, C. H., Zhu, T., Wu, Y. N., & Shoptaw, S. J. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09883-w · Cited by 30 · cited 2×
“Acceptance and Commitment Therapy vs CBT [81] More CBT sessions over fewer sessions, and CBT over self-help booklet with the exception of self-help booklet outperforming 1-session of CBT [27, 87, 88] • Variation in outcome results between ACT and CBT with no difference in harms [81] Other behavioural interventions (n…”
BackgroundReback, C. J., Rünger, D., Fletcher, J. B., & Swendeman, D. T. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.06.005 · Cited by 27 · cited 2×
“, incorporating self-monitoring), results were mixed depending on the outcome [71, 73] • Retention/dropout was favored for the Behavioural Activation + Sexual Risk Reduction counselling group over Sexual risk reduction counselling alone [68] • No studies reported on harms”
BackgroundResultNourredine, M., Jurek, L., Angerville, B., Longuet, Y., de Ternay, J., Derveaux, A., & Rolland, B. (2021) · CNS Drugs · doi:10.1007/s40263-020-00780-y · Cited by 26
Reinforcement Schedule Effects on Long-Term Behavior Change
Chudzynski, J., Roll, J. M., McPherson, S., Cameron, J. M., & Howell, D. N. (2015) · The Psychological Record · doi:10.1007/s40732-014-0110-3 · Cited by 25 · cited 2×
“Continuous; Intermittent predictable; Intermittent unpredictable CM; No TRT [52] 2.”
BackgroundThe influence of depression on treatment for methamphetamine use
Kay‐Lambkin, F. J., Baker, A. L., Lee, N. M., Jenner, L., & Lewin, T. J. (2011) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2011.tb03264.x · Cited by 25 · cited 9×
“When comparing number of session, 2-session CBT was favored when compared to the others [27, 87, 88].”
ResultInfluentialFarahzadi, M.-H., Moazen-Zadeh, E., Razaghi, E., Zarrindast, M.-R., Bidaki, R., & Akhondzadeh, S. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118817166 · Cited by 18 · cited 2×
“Acceptance and Commitment Therapy vs CBT [81] More CBT sessions over fewer sessions, and CBT over self-help booklet with the exception of self-help booklet outperforming 1-session of CBT [27, 87, 88] • Variation in outcome results between ACT and CBT with no difference in harms [81] Other behavioural interventions (n…”
BackgroundBriones, M., Shoptaw, S., Cook, R., Worley, M., Swanson, A.-N., Moody, D. E., Fang, W. B., Tsuang, J., Furst, B., & Heinzerling, K. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.04.023 · Cited by 17 · cited 7×
“Naltrexone; Placebo [55] 3.”
BackgroundInfluentialHamel, C., Corace, K., Hersi, M., Rice, D., Willows, M., Macpherson, P., Sproule, B., Flores-Aranda, J., Garber, G., Esmaeilisaraji, L., et al. (2020) · Systematic Reviews · doi:10.1186/s13643-020-01499-z · Cited by 17
Self-citationGhasemi, A., Estebsari, F., Bastaminia, A., Jamshidi, E., & Dastoorpoor, M. (2014) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.20024 · Cited by 16
A cost‐effectiveness analysis of modafinil therapy for psychostimulant dependence
Shearer, J., Shanahan, M., Darke, S. G., Rodgers, C., van Beek, I., McKetin, R., & Mattick, R. P. (2010) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2009.00148.x · Cited by 15 · cited 6×
“, related to degree of benefit) when compared to placebo depending on the outcome • Unclear reporting of results in the Topiramate study did not allow for determination of which was favored [57, 89] • Approximately half of the pharmacological therapy studies reported on harms often favoring placebo or no difference be…”
BackgroundResultInfluentialKamp, F., Hager, L., Proebstl, L., Schreiber, A., Riebschläger, M., Neumann, S., Straif, M., Schacht-Jablonowsky, M., Falkai, P., Pogarell, O. M., et al. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.05.029 · Cited by 12
Rawson, R. A., Gonzales, R. E., Greenwell, L., & Chalk, M. (2012) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2012.718653 · Cited by 11 · cited 2×
“Educational intervention; Treatment as usual [60] • Matrix model outperformed both treatment as usual [70, 94, 95] and inpatient residential rehabilitation [69] with the exception of retention/dropout, where inpatient residential rehabilitation was favored [69] • Other interventions (i.”
MethodWang, G., Ma, L., Liu, X., Yang, X., Zhang, S., Yang, Y., Xu, Z., & Hao, W. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00656 · Cited by 11 · cited 2×
“Citicoline; Placebo [51] • Paliperidone [83] and Citicoline [51] was mostly favored to placebo, and Bupropion [22, 50, 90] had unclear reporting of results.”
BackgroundSorsdahl, K., Stein, D. J., Pasche, S., Jacobs, Y., Kader, R., Odlaug, B., Richter, S., Myers, B., & Grant, J. E. (2021) · Addiction Science & Clinical Practice · doi:10.1186/s13722-020-00209-3 · Cited by 11
Abdoli, N., Farnia, V., Salemi, S., Tatari, F., Juibari, T. A., Alikhani, M., & Basanj, B. (2019) · Journal of Substance Use · doi:10.1080/14659891.2018.1549279 · Cited by 10
(2011) · PubMed · Cited by 8
Abdoli, N., Farnia, V., Radmehr, F., Alikhani, M., Moradinazar, M., Khodamoradi, M., Salemi, S., Rezaei, M., & Davarinejad, O. (2020) · Journal of Substance Use · doi:10.1080/14659891.2020.1851406 · Cited by 8
Health-related quality of life (HRQL) among methamphetamine users in treatment
Ciketic, S., McKetin, R., Doran, C. M., Najman, J. M., Veerman, L. J., & Hayatbakhsh, M. R. (2013) · Mental Health and Substance Use · doi:10.1080/17523281.2012.713390 · Cited by 6 · cited 3×
“, outpatient counseling, community-based residential rehabilitation and community-based detox [53, 91, 92], blended imaging desensitisation [102], educational intervention [60]) outperformed treatment as usual/no treatment for most outcomes (e.”
MethodResultMohtasham‐Amiri, Z., Mirzaee, B., & Sabet, M. S. (2016) · International Journal of Medical Research & Health Sciences · Cited by 6
fard, M. T., Mansouri, S. S., Jafari, A., & Vousooghi, N. (2020) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v19i10.23 · Cited by 6
Effect of add-on valproate on craving in methamphetamine depended patients: A randomized trial
Kheirabadi, G. R., Ghavami, M., Maracy, M. R., Salehi, M., & Sharbafchi, M. R. (2016) · Advanced Biomedical Research · doi:10.4103/2277-9175.187404 · Cited by 5 · cited 2×
“Acceptance and Commitment Therapy vs CBT [81] More CBT sessions over fewer sessions, and CBT over self-help booklet with the exception of self-help booklet outperforming 1-session of CBT [27, 87, 88] • Variation in outcome results between ACT and CBT with no difference in harms [81] Other behavioural interventions (n…”
BackgroundKheirabadi, G. R., Bahrami, M., Shariat, A., & Tarrahi, M. J. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001320 · Cited by 4
Noroozi, A., Motevalian, S. A., Zarindast, M., Alaghband‐Rad, J., & Akhondzadeh, S. (2020) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.34.137 · Cited by 4
Oral Manifestations of Illicit Drug Use
Bartold, P. M. (2019) · Australian Dental Journal · doi:10.1111/adj.12713 · Cited by 3
An assessment model for methamphetamine dependence treatment rehabilitation in Thailand
Perngparn, U., Limanonda, B., & Aramrattana, A. (2009) · Chula Digiverse · doi:10.58837/chula.the.2009.2305 · Cited by 1
Research works printed but not linked: 7
- M Kuo, 2012, Pilot project report: survey on drug use among harm reduction clients, British Columbia Center for Disease Control
- National Institute on Drug Abuse, 2023, What is the scope of methamphetamine use in the United States?
- NIH Research Matters, 2021, Trends in U.S. methamphetamine use and associated deaths
- European Monitoring Centre for Drugs and Drug Addiction, 2022, Signals of spreading methamphetamine use in Europe
- JPT Higgins, 2011, Part 2: General methods for Cochrane reviews
- WD Braunwarth, 2016, S3 practice guideline methamphetamine-related disorders
- Grigg J, Manning V, Arunogiri S et al. Methamphetamine Treatment Guidelines: Practice Guidelines for Health Professionals (2nd edition). Australia; 2018. Available: https://www.turningpoint.org.au/sites/default/files/2019-05/Turning-Point-Methamphetamine-Treatment-Guidelines.pdf
Cited by
Essential criteria for existence of solution of a modified-ABC fractional order smoking model
Khan, H., Alzabut, J., Gómez-Aguilar, J. F., et al. (2024) · Ain Shams Engineering Journal · doi:10.1016/j.asej.2024.102646 · Cited by 37
Community-Based Outreach for People Living With Methamphetamine-Associated Cardiomyopathy
Chiang, J. C., Pechan, J., Smith, K., et al. (2024) · JACC Case Reports · doi:10.1016/j.jaccas.2024.102598 · Cited by 3
Mechanisms underlying methamphetamine-induced disruption of testicular integrity
Adisa, F. B., Oyovwi, M. O., & Ajayi, A. F. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04311-8 · Cited by 3
“Chronic MA usage correlates with increased dental issues, including severe gum disease and tooth decay (Hersi et al. 2023).”
A Scoping Review of Cultural Variables in Contingency Management for Substance Use Disorder
Donohue, H. E., Foster, B. A., & Dallery, J. (2025) · Perspectives on Behavior Science · doi:10.1007/s40614-025-00480-2 · Cited by 3
Gujar, V. V., Daiwile, A. P., Palande, V., & Cadet, J. L. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.105980 · Cited by 3
Metadata
- Authors
- Hersi, M., Corace, K., Hamel, C., Esmaeilisaraji, L., Rice, D., Dryburgh, N., Skidmore, B., Garber, G., Porath, A., Willows, M., MacPherson, P., Sproule, B., Flores-Aranda, J., Dickey, C., & Hutton, B.
- Affiliations
- Ottawa Hospital Research Institute (CA)
- University of Ottawa (CA)
- McGill University (CA)
- Centre for Addiction and Mental Health (CA)
- Université du Québec à Montréal (CA)
- Western University (CA)
- Corresponding author
- Hutton, Brian
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2023-10-11
- Volume
- 18
- Issue
- 10
- Pages
- e0292745
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC10566716
- OpenAlex
- W4387526402
- Cited by
- 13
- References
- 101
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 2
- FWCI
- 0.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
- Keywords
- methamphetamine dependence, psychosocial interventions, pharmacological interventions, contingency management, topiramate, bupropion, modafinil, psychostimulants, treatment retention, relapse, substance use comorbidity, adolescents and youth, men who have sex with men, family support groups, self-help
- MeSH terms
- Sexual and Gender Minorities, Adolescent, Central Nervous System Stimulants, Artificial Intelligence, Humans, Male, Methamphetamine, Homosexuality, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

